Are Aarti Pharmalabs Ltd latest results good or bad?

Aarti Pharmalabs Ltd's financial results for Q4 FY26 present a complex picture of growth and challenges. The company reported consolidated net sales of ₹582.64 crores, reflecting a notable sequential growth of 34.79% from the previous quarter, driven by improved capacity utilization and a favorable product mix. However, the year-on-year comparison shows a modest increase of just 3.35% from ₹563.78 crores in Q4 FY25. On the profitability front, consolidated net profit reached ₹61.12 crores, which indicates a sequential improvement of 27.44%. Yet, this figure is significantly lower by 30.81% compared to the same quarter last year. The profit after tax (PAT) margin has also contracted to 10.49%, down from 15.67% a year earlier, highlighting a deterioration in the company's ability to convert revenue into profit amidst rising costs. Operating margins, excluding other income, fell to 19.42%, down from 23.67% in the previous quarter and 25.83% in the same quarter last year. This decline of 641 basis points year-on-year signals significant pricing pressures and cost inflation that the company has struggled to manage effectively. Additionally, interest costs surged to ₹16.86 crores, marking a substantial increase of 156.23% year-on-year, which adds further strain to the company's financial health. Overall, while Aarti Pharmalabs has achieved strong revenue growth on a sequential basis, the underlying profitability metrics reveal significant challenges. The company has experienced an adjustment in its evaluation, reflecting concerns over its financial performance and operational efficiency in a competitive market environment. Investors should closely monitor how management addresses these profitability pressures and the overall market conditions affecting the pharmaceutical sector.